176 related articles for article (PubMed ID: 32434789)
21. Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients.
Amaral T; Kiecker F; Schaefer S; Stege H; Kaehler K; Terheyden P; Gesierich A; Gutzmer R; Haferkamp S; Uttikal J; Berking C; Rafei-Shamsabadi D; Reinhardt L; Meier F; Karoglan A; Posch C; Gambichler T; Pfoehler C; Thoms K; Tietze J; Debus D; Herbst R; Emmert S; Loquai C; Hassel JC; Meiss F; Tueting T; Heinrich V; Eigentler T; Garbe C; Zimmer L;
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32221017
[TBL] [Abstract][Full Text] [Related]
22. COVID-19 Pneumonia Mimicking Immunotherapy-Induced Pneumonitis on 18F-FDG PET/CT in a Patient Under Treatment With Nivolumab.
Artigas C; Lemort M; Mestrez F; Gil T; Flamen P
Clin Nucl Med; 2020 Aug; 45(8):e381-e382. PubMed ID: 32520508
[TBL] [Abstract][Full Text] [Related]
23. Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma.
Versluis JM; Reijers ILM; Rozeman EA; Menzies AM; van Akkooi ACJ; Wouters MW; Ch'ng S; Saw RPM; Scolyer RA; van de Wiel BA; Schilling B; Long GV; Blank CU
Eur J Cancer; 2021 May; 148():51-57. PubMed ID: 33735809
[TBL] [Abstract][Full Text] [Related]
24. Checkpoint inhibitor pneumonitis mimicking COVID-19 infection during the COVID-19 pandemic.
Chang HL; Wei PJ; Wu KL; Huang HL; Yang CJ
Lung Cancer; 2020 Aug; 146():376-377. PubMed ID: 32576385
[No Abstract] [Full Text] [Related]
25. Effectiveness of Immune Checkpoint Inhibitor with Anti-PD-1 Monotherapy or in Combination with Ipilimumab in Younger versus Older Adults with Advanced Melanoma.
Woo TE; Stukalin I; Ding PQ; Goutam S; Sander M; Ewanchuk B; Cheung WY; Heng DYC; Cheng T
Curr Oncol; 2023 Sep; 30(10):8936-8947. PubMed ID: 37887546
[No Abstract] [Full Text] [Related]
26. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.
Larkin J; Chmielowski B; Lao CD; Hodi FS; Sharfman W; Weber J; Suijkerbuijk KPM; Azevedo S; Li H; Reshef D; Avila A; Reardon DA
Oncologist; 2017 Jun; 22(6):709-718. PubMed ID: 28495807
[TBL] [Abstract][Full Text] [Related]
27. Recurrent audiovestibular dysfunction and associated neurological immune-related adverse events in a melanoma patient treated with nivolumab and ipilimumab.
Choi JS; Chen M; McQuade JL; Appelbaum E; Gidley PW; Nader ME
Head Neck; 2020 Nov; 42(11):E35-E42. PubMed ID: 32888241
[TBL] [Abstract][Full Text] [Related]
28. Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis.
Alrabadi NN; Abushukair HM; Ababneh OE; Syaj SS; Al-Horani SS; Qarqash AA; Darabseh OA; Al-Sous MM; Al-Aomar SR; Ahmed YB; Haddad R; Al Qarqaz FA
Clin Transl Oncol; 2021 Sep; 23(9):1885-1904. PubMed ID: 33877531
[TBL] [Abstract][Full Text] [Related]
29. Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial.
Ascierto PA; Del Vecchio M; Mandalá M; Gogas H; Arance AM; Dalle S; Cowey CL; Schenker M; Grob JJ; Chiarion-Sileni V; Márquez-Rodas I; Butler MO; Maio M; Middleton MR; de la Cruz-Merino L; Arenberger P; Atkinson V; Hill A; Fecher LA; Millward M; Khushalani NI; Queirolo P; Lobo M; de Pril V; Loffredo J; Larkin J; Weber J
Lancet Oncol; 2020 Nov; 21(11):1465-1477. PubMed ID: 32961119
[TBL] [Abstract][Full Text] [Related]
30. Clinical Characteristics and Outcome for Four SARS-CoV-2-infected Cancer Patients Treated with Immune Checkpoint Inhibitors.
Szabados B; Abu-Ghanem Y; Grant M; Choy J; Bex A; Powles T
Eur Urol; 2020 Aug; 78(2):276-280. PubMed ID: 32534910
[TBL] [Abstract][Full Text] [Related]
31. Immune checkpoint inhibitors in SARS-CoV-2 infected cancer patients: the spark that ignites the fire?
Di Noia V; D'Aveni A; Squadroni M; Beretta GD; Ceresoli GL
Lung Cancer; 2020 Jul; 145():208-210. PubMed ID: 32439211
[No Abstract] [Full Text] [Related]
32. Comparative effectiveness of second-line ipilimumab vs. nivolumab in combination with ipilimumab in patients with advanced melanoma who received frontline anti-PD-1 antibodies.
Baron K; Moser JC; Patel S; Grossmann KF; Colonna SV; Hyngstrom JR
J Oncol Pharm Pract; 2021 Apr; 27(3):555-559. PubMed ID: 32423325
[TBL] [Abstract][Full Text] [Related]
33. Clinical course of COVID-19 infection in elderly patient with melanoma on nivolumab.
Yekedüz E; Dursun B; Aydın GÇ; Yazgan SC; Öztürk HH; Azap A; Utkan G; Ürün Y
J Oncol Pharm Pract; 2020 Jul; 26(5):1289-1294. PubMed ID: 32423324
[TBL] [Abstract][Full Text] [Related]
34. Pharmacovigilance Assessment of Immune-Mediated Reactions Reported for Checkpoint Inhibitor Cancer Immunotherapies.
Ali AK; Watson DE
Pharmacotherapy; 2017 Nov; 37(11):1383-1390. PubMed ID: 28950039
[TBL] [Abstract][Full Text] [Related]
35. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.
Hodi FS; Chiarion-Sileni V; Gonzalez R; Grob JJ; Rutkowski P; Cowey CL; Lao CD; Schadendorf D; Wagstaff J; Dummer R; Ferrucci PF; Smylie M; Hill A; Hogg D; Marquez-Rodas I; Jiang J; Rizzo J; Larkin J; Wolchok JD
Lancet Oncol; 2018 Nov; 19(11):1480-1492. PubMed ID: 30361170
[TBL] [Abstract][Full Text] [Related]
36. Multiple nivolumab-induced CNS demyelination with spontaneous resolution in an asymptomatic metastatic melanoma patient.
Pillonel V; Dunet V; Hottinger AF; Berthod G; Schiappacasse L; Peters S; Michielin O; Aedo-Lopez V
J Immunother Cancer; 2019 Dec; 7(1):336. PubMed ID: 31791418
[TBL] [Abstract][Full Text] [Related]
37. Calcium-sensing receptor autoantibody-mediated hypoparathyroidism associated with immune checkpoint inhibitor therapy: diagnosis and long-term follow-up.
Dadu R; Rodgers TE; Trinh VA; Kemp EH; Cubb TD; Patel S; Simon JM; Burton EM; Tawbi H
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581059
[TBL] [Abstract][Full Text] [Related]
38. Response to the Rechallenge With Talimogene Laherparepvec (T-VEC) After Ipilimumab/Nivolumab Treatment in Patient With Cutaneous Malignant Melanoma Who Initially Had a Progression on T-VEC With Pembrolizumab.
Afzal MZ; Shirai K
J Immunother; 2019 May; 42(4):136-141. PubMed ID: 30933044
[TBL] [Abstract][Full Text] [Related]
39. Low-dose ipilimumab combined with anti-PD-1 immunotherapy in patients with metastatic melanoma following anti-PD-1 treatment failure.
Klee G; Kurzhals J; Hagelstein V; Zillikens D; Recke A; Langan EA; Terheyden P
Melanoma Res; 2021 Oct; 31(5):464-471. PubMed ID: 34284462
[TBL] [Abstract][Full Text] [Related]
40. Immune checkpoint inhibitor-associated sarcoidosis: A usually benign disease that does not require immunotherapy discontinuation.
Chanson N; Ramos-Casals M; Pundole X; Suijkerbuijk K; José de Barros E Silva M; Lidar M; Benesova K; Leipe J; Acar-Denizli N; Pradère P; Michot JM; Voisin AL; Suárez-Almazor ME; Radstake TRD; Fernandes Moça Trevisani V; Schulze-Koops H; Melin A; Robert C; Mariette X; Baughman RP; Lambotte O; ; ; ; ; ;
Eur J Cancer; 2021 Nov; 158():208-216. PubMed ID: 34452793
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
